1. Scrip
  2. >>Drug Pricing

NICE No For AZ's Tagrisso Highlights Flaws of England's New Cancer Drugs Fund

 
• By Francesca Bruce

NICE, the HTA institute for England and Wales, has said a preliminary no to AstraZeneca PLC 's lung cancer drug Tagrisso (osimertinib). According to the firm, the decision shows that certain drugs will fare badly under NICE's new system for assessing cancer drugs.

Thumbs down

NICE, the HTA institute for England and Wales, has doubts over the long-term benefits of AstraZeneca PLC's Tagrisso (osimertinib) and has initially declined to recommend the drug either for conditional funding through the new Cancer Drugs Fund or for routine NHS funding. The draft guidance "highlights major issues with the current NICE process" with respect to appraising medicines that have been awarded early authorization, says Greg Rossi, business unit head, oncology, at AstraZeneca.

"Due to the uncertainties in the evidence and because it could not be considered cost-effective, the committee concluded that osimertinib did not meet the criteria

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’